ClinicalTrials.gg
RecruitingNCT07408219RELIEFUpdated Nov 20, 2026

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

An observational study in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Chronic Urticaria by Novartis — 7 open to participants now, 12 under way, 5 of them phase 3. Chronic Urticaria · Novartis.

Planned enrollment
7th of 10
350 · median 484
Started
2026
with 6 others
Observational
10 of 38
5 open now
Primary completion
2026-12
later than 4 of 11 live
Registered
34th of 38
by date

Among the 38 studies in Chronic Urticaria by Novartis, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2026, is one of 10 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 34th registered.

Chronic Urticaria

199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

7 of the 38 studies in Chronic Urticaria by Novartis are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Chronic Urticaria by Novartis, or all of them as a file.
02

Study summary

This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • Chronic spontaneous urticaria
  • Remibrutinib
  • Dupilumab
  • Urticaria control test
  • Urticaria control test 7 day recall
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

CSU patients who are prescribed and initiating treatment with remibrutinib or dupilumab, and who are invited to participate following a referral from their HCP.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthcare provider (HCP) participants eligible to refer patients for inclusion in this study must meet all the following criteria:

  1. Have an active medical license and be board certified/board eligible allergist or dermatologist in the US. Nurse practitioners and physician assistant practicing in allergy and dermatology are eligible.
  2. Manage CSU patients within their practice.
  3. Enrolled in the research network or are referred HCPs who agree to participate.
  4. Have the requisite patient population based on study inclusion/exclusion criteria.

    Patients eligible for inclusion in this study must meet all of the following criteria:

  5. ≥ 18 years of age.
  6. Diagnosed with CSU by an HCP.
  7. Have received a prescription for remibrutinib or dupilumab and are expected to initiate treatment.
  8. Have access to an electronic device with internet capabilities.
  9. Able to read and understand English.
  10. Willing and able to provide consent for study participation.

Exclusion criteria

Exclusion criteria:

Patients will be excluded if they meet any of the following criteria:

  1. Unable to procure remibrutinib or dupilumab (through samples, commercially or patient assistance program).
  2. Exposure to oral treatment in 14 days prior to consent.
  3. Exposure to oral corticosteroid treatment in 14 days prior to initiating treatment with remibrutinib or dupilumab.
  4. Prior participation in a remibrutinib or dupilumab clinical trial.
  5. Cognitive impairment that impacts the patient's ability to participate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Groups and cohorts

  • Remibrutinib Cohort

    Adult patients with CSU who are prescribed and initiating treatment with remibrutinib.

  • Dupilumab Cohort

    Adult patients with CSU who are prescribed and initiating treatment with dupilumab.

This study also gives DupilumabStudies of DupilumabDupilumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., RemibrutinibStudies of RemibrutinibRemibrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Urticaria Control Test - 7 Day Recall (UCT-7) Score at Week 4 in Patients Initiating Remibrutinib

    UCT-7 is a validated PRO tool designed to assess disease control over a 7-day recall period. It evaluates symptom burden, quality of life impact, treatment adequacy, and overall disease control. It consists of 4 questions, each of which is scored 0-4, with a total score range of 0-16. A score of \<12 indicates poor disease control, 12-15 = partial control, and 16 indicates complete control.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Change From Baseline in UCT-7 Score at Week 1 in Patients Initiating Remibrutinib

    UCT-7 is a validated PRO tool designed to assess disease control over a 7-day recall period. It evaluates symptom burden, quality of life impact, treatment adequacy, and overall disease control. It consists of 4 questions, each of which is scored 0-4, with a total score range of 0-16. A score of \<12 indicates poor disease control, 12-15 = partial control, and 16 indicates complete control.

    Time frame: Baseline and Week 1

  2. Proportion of Patients With a UCT-7 Score ≥12 at Week 1 and Week 4 in Patients Initiating Remibrutinib

    UCT-7 is a validated PRO tool designed to assess disease control over a 7-day recall period. It evaluates symptom burden, quality of life impact, treatment adequacy, and overall disease control. It consists of 4 questions, each of which is scored 0-4, with a total score range of 0-16. A score of \<12 indicates poor disease control, 12-15 = partial control, and 16 indicates complete control.

    Time frame: Week 1 and Week 4

  3. Treatment Satisfaction Questionnaire for Medication - Version 9 (TSQM-9) Domain Scores at Week 4 in Patients Initiating Remibrutinib

    The TSQM-9 is a validated PRO tool used to determine patient perceptions of the benefits, convenience, and overall satisfaction with their CSU treatment. It asks about 3 domains: effectiveness, convenience, and global satisfaction. TSQM-9 domain scores range from 0 to 100, with higher scores indicating greater satisfaction for that domain.

    Time frame: Week 4

  4. Change From Baseline in TSQM-9 Domain Scores at Week 4 in Patients Initiating Remibrutinib

    The TSQM-9 is a validated PRO tool used to determine patient perceptions of the benefits, convenience, and overall satisfaction with their CSU treatment. It asks about 3 domains: effectiveness, convenience, and global satisfaction. TSQM-9 domain scores range from 0 to 100, with higher scores indicating greater satisfaction for that domain. A positive change from baseline indicates improvement.

    Time frame: Baseline and Week 4

  5. Treatment Satisfaction Assessed by TSQM-9 Overall Score at Week 4 in Patients Initiating Remibrutinib

    The TSQM-9 is a validated PRO tool used to determine patient perceptions of the benefits, convenience, and overall satisfaction with their CSU treatment. It asks about 3 domains: effectiveness, convenience, and global satisfaction. TSQM-9 domain scores range from 0 to 100, with higher scores indicating greater satisfaction for that domain. Scores are produced for each domain, and total scores are calculated and used to assess overall medication satisfaction.

    Time frame: Week 4

  6. Change From Baseline in TSQM-9 Overall Score at Week 4 in Patients Initiating Remibrutinib

    The TSQM-9 is a validated PRO tool used to determine patient perceptions of the benefits, convenience, and overall satisfaction with their CSU treatment. It asks about 3 domains: effectiveness, convenience, and global satisfaction. TSQM-9 domain scores range from 0 to 100, with higher scores indicating greater satisfaction for that domain. Scores are produced for each domain, and total scores are calculated and used to assess overall medication satisfaction. A positive change from baseline indicates improvement.

    Time frame: Baseline and Week 4

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 13, 2026
StartActual
Jan 17, 2026
Primary completionEst.
Dec 31, 2026was Sep 2026
CompletionEst.
Dec 31, 2026was Sep 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Dec 31, 2026
Nov 20, 2026
Study completion
Sep 30, 2026→Dec 31, 2026
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Sep 30, 2026→Dec 31, 2026
    Study completion Sep 30, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07408219
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Jan 17, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 20, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion